Search results
Results from the Think 24/7 Content Network
3,4-Methylenedioxyamphetamine (also known as MDA and sass) is an empathogen-entactogen, psychostimulant, and psychedelic drug of the amphetamine family that is encountered mainly as a recreational drug. In its pharmacology, MDA is a serotonin–norepinephrine–dopamine releasing agent (SNDRA). In most countries, the drug is a controlled ...
MDAI (5,6-methylenedioxy-2-aminoindane) is a drug developed in the 1990s by a team led by David E. Nichols at Purdue University. It acts as a non- neurotoxic and highly selective serotonin releasing agent (SSRA) in vitro and produces entactogen effects in humans.
Mephedrone. Not to be confused with methedrine, methedrone, mephedrene, methadone, methylone, methcathinone, or ephedrone. Mephedrone, also known as 4-methylmethcathinone, 4-MMC, and 4-methylephedrone, is a synthetic stimulant drug of the amphetamine and cathinone classes. Slang names include drone, [ 5 ]M-CAT, [ 6 ]White Magic, [ 7 ]meow meow ...
You can find instant answers on our AOL Mail help page. Should you need additional assistance we have experts available around the clock at 800-730-2563.
This class of drugs are mimics of serotonin that activate 5-HT receptor subtypes that release norepinephrine and dopamine. 2C-B-BZP. 3-Chlorophenylpiperazine, meta-Chlorophenylpiperazine, mCPP. 4-Fluorophenylpiperazine, para-Fluorophenylpiperazine, pFPP, 4-FPP, Fluoperazine, Flipiperazine.
6-APB ( 6- (2-aminopropyl)benzofuran) is an empathogenic psychoactive compound of the substituted benzofuran and substituted phenethylamine classes. [ 1] 6-APB and other compounds are sometimes informally called "Benzofury" in newspaper reports. It is similar in structure to MDA, but differs in that the 3,4- methylenedioxyphenyl ring system has ...
The American Hospital Directory lists 145 hospitals in Arizona, which had a population of 7,151,502 in 2020. In 2020, these hospitals had 13,296 staffed beds. The largest hospitals, based on beds, is the Banner University Medical Center in Phoenix with 712 beds. There is a hospital run by the Mayo Clinic in Phoenix.
MDMAI. 5,6-Methylenedioxy-N-methyl-2-aminoindane ( MDMAI ), is a drug developed in the 1990s by a team led by David E. Nichols at Purdue University. It acts as a non- neurotoxic and highly selective serotonin releasing agent (SSRA) in animals and a putative entactogen in humans. [1]